The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

• Status: Terminated
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of our study is primarily to evaluate the effects of 5mg finasteride on hematuria and hematospermia commonly associated with prostate biopsies. We hypothesize that 5mg of finasteride daily for two weeks preceding TRUS prostate biopsy and one week following will reduce hematuria and hematospermia commonly seen as complications following prostate biopsy. We also hypothesize that reducing complications will decrease concern among subjects and make for a more tolerable overall procedure than compared with subjects treated with placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborators: Health Canada; Merck Frosst Canada Ltd.
• Treatments: Finasteride

Criteria

Inclusion Criteria:

1. Written informed consent prior to the participation in any study related activity.

2. Male subject already identified as requiring TRUS prostate biopsy for unrelated medical reasons.

Exclusion Criteria:

1. Suspected or known liver disease.

2. Suspected or known hematological disorders.

3. Subjects who are candidates for immediate surgery.

4. Known hypersensitivity to any component of the product.